Return-path: <jsardaryan@oct-clinicaltrials.com>
Envelope-to: info@riw-sv.com
Delivery-date: Tue, 09 Oct 2012 06:14:21 -0500
Received: from worker.out-clinicaltrials.com ([213.33.233.102]:11771 helo=worker.oct-clinicaltrials.com)
	by sprinter.websitewelcome.com with esmtp (Exim 4.80)
	(envelope-from <jsardaryan@oct-clinicaltrials.com>)
	id 1TLXlV-0007mR-26
	for info@riw-sv.com; Tue, 09 Oct 2012 06:14:21 -0500
X-MimeOLE: Produced By Microsoft Exchange V6.5
Content-class: urn:content-classes:message
Return-Receipt-To: "Julia Sardaryan" <jsardaryan@oct-clinicaltrials.com>
MIME-Version: 1.0
Content-Type: multipart/related;type="multipart/alternative";boundary="----_=_NextPart_001_01CDA60F.395DCA72"
Disposition-Notification-To: "Julia Sardaryan" <jsardaryan@oct-clinicaltrials.com>
Subject: Russian Innovation Week 
Date: Tue, 9 Oct 2012 15:14:17 +0400
Message-ID: <2C3C127A44B22D4B9C0D8A77E4ADF62C02ED6ECE@worker.octspb.ru>
X-MS-Has-Attach: 
X-MS-TNEF-Correlator: 
Thread-Topic: Russian Innovation Week 
Thread-Index: Ac2mDLTVQfgRBud3SM6h4hRelnBHzQ==
From: "Julia Sardaryan" <jsardaryan@oct-clinicaltrials.com>
To: <info@riw-sv.com>
Cc: "Dmitry Sharov" <sharov@oct-clinicaltrials.com>

This is a multi-part message in MIME format.

------_=_NextPart_001_01CDA60F.395DCA72
Content-Type: multipart/alternative;boundary="----_=_NextPart_002_01CDA60F.395DCA72"


------_=_NextPart_002_01CDA60F.395DCA72
Content-Type: text/plain;charset="koi8-r"
Content-Transfer-Encoding: quoted-printable

Dear Sir/Madam!

Can you please let us know if OCT can get the invitation to participate at t=
he Russian Innovative Week in Mountain View. OCT CEO, Dmitry Sharov, would l=
ike to attend the conference if such an opportunity exists.

We tried to register online but we did not get any confirmation.

Thank you in advance!

Best wishes,

Julia

 

Julia (Nedokusheva) Sardaryan

Head of Business Development

-------------------------------------------------------------
OCT - Clinical Trials in Central and Eastern Europe
191002, St. Petersburg, Russia
8/2 Bolshaya Moskovskaya St., Let. "A",  suite 4-1


Work: +7 (812) 449-86-34 ext. 2022 <tel:%2B7%20%28812%29%20449-86-34%20ext.%=
202022> 

Fax: +7 (812) 449-86-35 <tel:%2B7%20%28812%29%20449-86-35> 
Mobile: +7 (921) 300-86-18 <tel:%2B7%20%28921%29%20300-86-18> 
jsardaryan@oct-clinicaltrials.com <mailto:jnedokusheva@oct-clinicaltrials.co=
m> 
www.oct-clinicaltrials.com <http://www.oct-clinicaltrials.com/> 

  <http://www.facebook.com/pages/OCT-Clinical-Trials-in-Central-and-Eastern-=
Europe/196132447115440>    <http://www.linkedin.com/company/oct-clinical-tri=
als-in-central-and-eastern-europe>    <https://twitter.com/#!/CRO_Europe> 

 

 

 

 





IMPORTANT NOTICE - The information (both of the message and any attachments)=
 contained in this message is intended only for the use of the individual or=
 entity to which it is addressed and may contain information that is privile=
ged, confidential and exempt from disclosure under applicable law. If the re=
ader of this message is not the intended recipient or an agent responsible f=
or delivering it to an intended recipient or has received this message in er=
ror, you are hereby notified that we do not consent to any reading, dissemin=
ation, distribution or copying of this message and any such actions are stri=
ctly prohibited. If you have received this message in error, please notify t=
he sender immediately and destroy the transmitted information.


------_=_NextPart_002_01CDA60F.395DCA72
Content-Type: text/html;charset="koi8-r"
Content-Transfer-Encoding: quoted-printable

<html xmlns:v=3D"urn:schemas-microsoft-com:vml" xmlns:o=3D"urn:schemas-micro=
soft-com:office:office" xmlns:w=3D"urn:schemas-microsoft-com:office:word" xm=
lns:m=3D"http://schemas.microsoft.com/office/2004/12/omml" xmlns=3D"http://w=
ww.w3.org/TR/REC-html40"><head><meta http-equiv=3DContent-Type content=3D"te=
xt/html; charset=3Dkoi8-r"><meta name=3DGenerator content=3D"Microsoft Word =
14 (filtered medium)"><!--[if !mso]><style>v\:* {behavior:url(#default#VML);=
}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><style><!--
/* Font Definitions */
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Calibri","sans-serif";}
a:link, span.MsoHyperlink
	{mso-style-priority:99;
	color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{mso-style-priority:99;
	color:purple;
	text-decoration:underline;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-priority:99;
	mso-style-link:"Balloon Text Char";
	margin:0in;
	margin-bottom:.0001pt;
	font-size:8.0pt;
	font-family:"Tahoma","sans-serif";}
span.EmailStyle17
	{mso-style-type:personal-compose;
	font-family:"Calibri","sans-serif";
	color:windowtext;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-priority:99;
	mso-style-link:"Balloon Text";
	font-family:"Tahoma","sans-serif";}
.MsoChpDefault
	{mso-style-type:export-only;
	font-family:"Calibri","sans-serif";}
@page WordSection1
	{size:8.5in 11.0in;
	margin:56.7pt 42.5pt 56.7pt 85.05pt;}
div.WordSection1
	{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext=3D"edit" spidmax=3D"1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext=3D"edit">
<o:idmap v:ext=3D"edit" data=3D"1" />
</o:shapelayout></xml><![endif]--></head><body lang=3DEN-US link=3Dblue vlin=
k=3Dpurple><div class=3DWordSection1><p class=3DMsoNormal>Dear Sir/Madam!<o:=
p></o:p></p><p class=3DMsoNormal>Can you please let us know if OCT can get t=
he invitation to participate at the Russian Innovative Week in Mountain View=
. OCT CEO, Dmitry Sharov, would like to attend the conference if such an opp=
ortunity exists.<o:p></o:p></p><p class=3DMsoNormal>We tried to register onl=
ine but we did not get any confirmation.<o:p></o:p></p><p class=3DMsoNormal>=
Thank you in advance!<o:p></o:p></p><p class=3DMsoNormal>Best wishes,<o:p></=
o:p></p><p class=3DMsoNormal>Julia<o:p></o:p></p><p class=3DMsoNormal><o:p>&=
nbsp;</o:p></p><p class=3DMsoNormal><b><span style=3D'color:#006699;mso-fare=
ast-language:RU'>Julia (Nedokusheva) Sardaryan<o:p></o:p></span></b></p><p c=
lass=3DMsoNormal><span style=3D'color:#006699;mso-fareast-language:RU'>Head =
of Business&nbsp;Development<o:p></o:p></span></p><p class=3DMsoNormal><span=
 style=3D'color:#006699;mso-fareast-language:RU'>---------------------------=
----------------------------------<br><b>OCT &#8211; Clinical Trials in Cent=
ral and Eastern Europe</b></span><span style=3D'font-size:9.0pt;color:#00669=
9;mso-fareast-language:RU'><br>191002, St. Petersburg, Russia<br>8/2 Bolshay=
a Moskovskaya St., Let. &#8220;A&#8221;, &nbsp;suite 4-1<o:p></o:p></span></=
p><p class=3DMsoNormal><span style=3D'font-size:9.0pt;color:#006699;mso-fare=
ast-language:RU'><br>Work:&nbsp;</span><span lang=3DRU style=3D'color:#1F497=
D;mso-fareast-language:RU'><a href=3D"tel:%2B7%20%28812%29%20449-86-34%20ext=
.%202022" target=3D"_blank"><span lang=3DEN-US style=3D'font-size:9.0pt;colo=
r:#006699'>+7 (812) 449-86-34 ext. 2022</span></a></span><span style=3D'font=
-size:9.0pt;color:#006699;mso-fareast-language:RU'><o:p></o:p></span></p><p =
class=3DMsoNormal><span style=3D'font-size:9.0pt;color:#006699;mso-fareast-l=
anguage:RU'>Fax: </span><span lang=3DRU style=3D'color:#1F497D;mso-fareast-l=
anguage:RU'><a href=3D"tel:%2B7%20%28812%29%20449-86-35" target=3D"_blank"><=
span lang=3DEN-US style=3D'font-size:9.0pt;color:#006699'>+7 (812) 449-86-35=
</span></a></span><span style=3D'font-size:9.0pt;color:#006699;mso-fareast-l=
anguage:RU'><br>Mobile: </span><span lang=3DRU style=3D'color:#1F497D;mso-fa=
reast-language:RU'><a href=3D"tel:%2B7%20%28921%29%20300-86-18" target=3D"_b=
lank"><span lang=3DEN-US style=3D'font-size:9.0pt;color:#006699'>+7 (921) 30=
0-86-18</span></a></span><span style=3D'font-size:9.0pt;color:#006699;mso-fa=
reast-language:RU'><br></span><span lang=3DRU style=3D'color:#1F497D;mso-far=
east-language:RU'><a href=3D"mailto:jnedokusheva@oct-clinicaltrials.com" tar=
get=3D"_blank" title=3D"blocked::mailto:gandreyev@out-clinicaltrials.com"><s=
pan lang=3DEN-US style=3D'font-size:9.0pt;color:#006699'>jsardaryan@oct-clin=
icaltrials.com</span></a></span><span style=3D'font-size:9.0pt;color:#006699=
;mso-fareast-language:RU'><br></span><span lang=3DRU style=3D'color:#1F497D;=
mso-fareast-language:RU'><a href=3D"http://www.oct-clinicaltrials.com/" targ=
et=3D"_blank" title=3D"blocked::http://www.out-clinicaltrials.com/"><span la=
ng=3DEN-US style=3D'font-size:9.0pt;color:#006699'>www.oct-clinicaltrials.co=
m</span></a></span><span style=3D'font-size:9.0pt;color:#006699;mso-fareast-=
language:RU'><o:p></o:p></span></p><p class=3DMsoNormal><a href=3D"http://ww=
w.facebook.com/pages/OCT-Clinical-Trials-in-Central-and-Eastern-Europe/19613=
2447115440"><span style=3D'font-size:9.0pt;color:#006699;text-decoration:non=
e'><img border=3D0 width=3D15 height=3D15 id=3D"=F2=C9=D3=D5=CE=CF=CB_x0020_=
1" src=3D"cid:image001.gif@01CDA630.AB7A4350" alt=3D"Description: =EF=D0=C9=D3=
=C1=CE=C9=C5: Description: Adobe Systems"></span></a><span style=3D'font-siz=
e:9.0pt;color:#006699;mso-fareast-language:RU'>&nbsp;</span><a href=3D"http:=
//www.linkedin.com/company/oct-clinical-trials-in-central-and-eastern-europe=
"><span style=3D'font-size:9.0pt;color:#006699;text-decoration:none'><img bo=
rder=3D0 width=3D15 height=3D15 id=3D"=F2=C9=D3=D5=CE=CF=CB_x0020_2" src=3D"=
cid:image002.png@01CDA630.AB7A4350" alt=3D"Description: =EF=D0=C9=D3=C1=CE=C9=
=C5: Description: Adobe Systems"></span></a><span style=3D'font-size:9.0pt;c=
olor:#006699;mso-fareast-language:RU'>&nbsp;</span><a href=3D"https://twitte=
r.com/#!/CRO_Europe"><span style=3D'font-size:9.0pt;color:#006699;text-decor=
ation:none'><img border=3D0 width=3D12 height=3D12 id=3D"=F2=C9=D3=D5=CE=CF=CB=
_x0020_3" src=3D"cid:image003.png@01CDA630.AB7A4350" alt=3D"Description: =EF=
=D0=C9=D3=C1=CE=C9=C5: Description: twitter.png"></span></a><span style=3D'f=
ont-size:9.0pt;color:#006699;mso-fareast-language:RU'><o:p></o:p></span></p>=
<p class=3DMsoNormal><o:p>&nbsp;</o:p></p><p class=3DMsoNormal><o:p>&nbsp;</=
o:p></p><p class=3DMsoNormal><o:p>&nbsp;</o:p></p><p class=3DMsoNormal><o:p>=
&nbsp;</o:p></p></div><SPAN class=3Du-2-msonormal style=3D"MARGIN: 0cm 0cm 0=
pt"><IMG height=3D15 alt=3DOCT-hor.gif src=3D"http://www.oct-clinicaltrials.=
com/images/image001.gif" width=3D226 border=3D0 v:shapes=3D"=F2=C9=D3=D5=CE=CF=
=CB_x0020_3"></SPAN>&nbsp;<SPAN lang=3DEN-US style=3D"FONT-SIZE: 9pt; COLOR:=
 #365f91; FONT-FAMILY: 'Arial','sans-serif'; mso-ansi-language: EN-US"><BR s=
tyle=3D"mso-special-character: line-break"></SPAN><B><SPAN style=3D"FONT-SIZ=
E: 8pt; COLOR: #365f91; FONT-FAMILY: 'Arial','sans-serif'"><O:P></O:P></SPAN=
></B>
<P></P>
<P class=3Du-2-msonormal style=3D"MARGIN: 0cm 0cm 0pt"><SPAN lang=3DEN-US st=
yle=3D"FONT-SIZE: 7pt; COLOR: #365f91; FONT-FAMILY: 'Arial','sans-serif'; ms=
o-ansi-language: EN-US">IMPORTANT NOTICE - The information (both of the mess=
age and any attachments) contained in this message is intended only for the =
use of the individual or entity to which it is addressed and may contain inf=
ormation that is privileged, confidential and exempt from disclosure under a=
pplicable law. If the reader of this message is not the intended recipient o=
r an agent responsible for delivering it to an intended recipient or has rec=
eived this message in error, you are hereby notified that we do not consent =
to any reading, dissemination, distribution or copying of this message and a=
ny such actions are strictly prohibited. If you have received this message i=
n error, please notify the sender immediately and destroy the transmitted in=
formation.<O:P></O:P></SPAN></P><A title=3D"gfidisc.oct-clinicaltrials.com" =
href=3D"#">  </A></body></html>
------_=_NextPart_002_01CDA60F.395DCA72--

------_=_NextPart_001_01CDA60F.395DCA72
Content-Type: image/gif;name="image001.gif"
Content-Transfer-Encoding: base64
Content-ID: <image001.gif@01CDA630.AB7A4350>
Content-Description: image001.gif
Content-Location: image001.gif
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------_=_NextPart_001_01CDA60F.395DCA72
Content-Type: image/png;name="image002.png"
Content-Transfer-Encoding: base64
Content-ID: <image002.png@01CDA630.AB7A4350>
Content-Description: image002.png
Content-Location: image002.png
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------_=_NextPart_001_01CDA60F.395DCA72
Content-Type: image/png;name="image003.png"
Content-Transfer-Encoding: base64
Content-ID: <image003.png@01CDA630.AB7A4350>
Content-Description: image003.png
Content-Location: image003.png
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==
------_=_NextPart_001_01CDA60F.395DCA72--
